FDA Grants Priority Review for Spesolimab | BI US
Read more about Spesolimab, which has been approved by the FDA as a treatment option for generalized pustular psoriasis (GPP) flares in adults.
Search
Targeting HER2 in cancer
Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.
First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US
Boehringer Ingelheim and Eli Lilly and Company today announced that the EMPEROR HF (heart failure) clinical trial program was initiated.
Prescription Digital Therapeutics a New Frontier in Mental Health Care
Overview of the gap in treatment accessibility for people with mental health conditions like schizophrenia and the potential applications of PDTs.
FIBRONEER™ trials for IPF, other progressive fibrosing ILDs
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program
FDA Grants Fast Track to Jardiance® (empagliflozin) for CKD | Boehringer Ingelheim US
The FDA has granted Fast Track designation for JARDIANCE to reduce risk of disease progression and CV death with CKD. View ISI, PI & Med Guide.
Express Scripts Adds BI Products to Roster | BI US
Read more on Express Scripts adding the Spiriva Respimat, Spiriva Handihaler and Stiolto Respimat to their commercial national preferred formulary.
Schizophrenia: Trial Results Show Advance in Cognition | BI US
Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary endpoint.
Dr. Wolchinsky Receives Pioneer Award | Boehringer Ingelheim US
Read more about Dr. Steven Wolchinsky receiving the first Vetmedin® (pimobendan) Cardiology Pioneer award, for his work and commitment to animal health.
Our evolved employer value proposition
Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.
Boehringer welcomes 2023 Gold Report
Boehringer welcomes 2023 GOLD Report Positioning LAMA/LABA as preferred treatment
Interview with Norbert Kraut: How cancer drives us forward
Norbert Kraut, our Global Head of Cancer Research at Boehringer Ingelheim, shares our approach to advancing cancer research and exploring new technologies
Anna Mistrioti
Anna Mistrioti speaks about working as a Quality Control Compliance Officer in Boehringer Ingelheim, in the Koropi Plant of Greece.
Fighting Non-Communicable Diseases | Boehringer Ingelheim US
Read more on Boehringer Ingelheim's new NCD initiative, aiming to reduce NCD prevalence and capture the impact of our product portfolio for our patients.
FDA accepts sNDA for children/adolescents with fibrosing ILD
U.S. FDA accepts sNDA for OFEV® (nintedanib) for the potential treatment of children and adolescents aged 6-17 with fibrosing interstitial lung disease
The Research Process
The Research Process
Fighting Rabies in Madagascar | Boehringer Ingelheim US
Find out more about the Boehringer Ingelheim efforts to fight Rabies in Madagascar. Hear from a veterinarian who administered 75,000 vaccines to cats & dogs on the island.
Ridgefield, CT | BI Facilities
BI was established in Connecticut in 1971 and broke ground on September 1st, 1989 in Ridgefield. This site is home to the U.S. HQ of Boehringer Ingelheim
FDA accepts Jardiance sNDA for T2D in children 10 and older
The US FDA has accepted a supplemental New Drug Application for Jardiance® (empagliflozin) tablets as a potential treatment for children 10 years and older with type 2 diabetes
Simon Manyara
Simon Manhara works with our culture and sustainability team towards making a positive social impact and creating a sustainable future.
Stefanie Bock Kreilinger
Stefanie Bock-Kreilinger works in the legal department at Boehringer Ingelheim as head of corporate legal medicine, evidence and digital health.
Liliana Montano
Liliana Montano works as a scientist within the Global Innovation and Alliance Management and talks about her journey at Boehringer Ingelheim.
Simon Heinrich
Simon Heinrich, an automation engineer in the Engineering and Facilities department, provides an in-depth look at working life at Boehringer Ingelheim.
OUR FOCUS
Our FOCUS is the cultural framework for our company. It describes who we are and what we strive for, why we exist, how we work and what we want to achieve.
Boehringer Ingelheim announces InPedILD PhaseIII trial results
Boehringer Ingelheim announces InPedILD PhaseIII trial results